# Community-Acquired Pneumonia (CAP)

## Definition
Pneumonia acquired outside of hospitals or long-term care facilities, presenting with acute respiratory symptoms and radiographic infiltrate in a patient not hospitalized in the prior 48 hours.

## CURB-65 Severity Score
Assign 1 point for each criterion:
- **C**onfusion (AMT score <=8 or new disorientation)
- **U**rea > 7 mmol/L (BUN > 20 mg/dL)
- **R**espiratory rate >= 30 breaths/min
- **B**lood pressure (SBP < 90 mmHg or DBP <= 60 mmHg)
- Age **65** years or older

### Disposition by Score
- **0-1**: Outpatient management; low mortality risk (~1-3%)
- **2**: Consider short inpatient stay or closely supervised outpatient care; mortality ~9%
- **3-5**: Inpatient admission required; scores of 4-5 warrant ICU evaluation; mortality 15-40%

## Common Pathogens

### Typical Organisms
- *Streptococcus pneumoniae* (most common overall)
- *Haemophilus influenzae* (especially COPD patients)
- *Moraxella catarrhalis*
- *Staphylococcus aureus* (post-influenza, IV drug use)

### Atypical Organisms
- *Mycoplasma pneumoniae* (younger adults, gradual onset)
- *Chlamydophila pneumoniae*
- *Legionella pneumophila* (contaminated water exposure; check urine antigen)

## Empiric Antibiotic Therapy

### Outpatient (No Comorbidities)
- Amoxicillin 1g PO TID **or**
- Doxycycline 100 mg PO BID
- Duration: 5 days minimum (extend if not clinically stable by day 3)

### Outpatient (With Comorbidities: COPD, DM, CKD, heart failure, alcoholism)
- Amoxicillin-clavulanate 875/125 mg PO BID **plus** a macrolide (azithromycin 500 mg day 1 then 250 mg days 2-5) **or**
- Respiratory fluoroquinolone monotherapy (levofloxacin 750 mg PO daily or moxifloxacin 400 mg PO daily)

### Inpatient (Non-ICU)
- Beta-lactam (ceftriaxone 1-2 g IV daily or ampicillin-sulbactam 3 g IV q6h) **plus** macrolide (azithromycin 500 mg IV/PO daily) **or**
- Respiratory fluoroquinolone monotherapy IV

### Inpatient (ICU)
- Beta-lactam (ceftriaxone 2 g IV daily or ampicillin-sulbactam 3 g IV q6h) **plus** macrolide or fluoroquinolone
- If *Pseudomonas* risk: piperacillin-tazobactam 4.5 g IV q6h or cefepime 2 g IV q8h **plus** fluoroquinolone
- If MRSA risk (prior MRSA, cavitary infiltrate): add vancomycin 15-20 mg/kg IV q8-12h or linezolid 600 mg IV/PO q12h

## Admission Criteria (Beyond CURB-65)
- Hypoxemia: SpO2 < 94% on room air or PaO2 < 60 mmHg
- Multilobar infiltrates on chest imaging
- Hemodynamic instability or need for vasopressors
- Inability to tolerate oral medications (persistent vomiting)
- Significant comorbid decompensation
- Social factors precluding safe outpatient management

## Treatment Duration and Follow-Up
- Standard duration: 5 days if afebrile for >= 48 hours and clinically improving
- Longer courses (7-10 days) for *Pseudomonas*, MRSA, lung abscess, or empyema
- Follow-up chest radiograph at 6-8 weeks for smokers aged > 50 to exclude underlying malignancy
- Procalcitonin may guide antibiotic discontinuation (stop if < 0.25 ng/mL and clinical improvement)

## Prevention
- Pneumococcal vaccination: PCV20 for all adults >= 65 and high-risk adults 19-64
- Annual influenza vaccination
- Smoking cessation counseling
